‌

US Patent 9512226 Agent for treating disease

Patent 9512226 was granted and assigned to Biotest AG on December, 2016 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Current Assignee

Biotest AG

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

95122260

Patent Inventor Names

Silke Aigner0

Juergen Lindner0

Matthias Germer0

Sibylle Kaiser0

Andrea Wartenberg-Demand0

Benjamin Daelken0

Christoph Bruecher0

Christoph Uherek0

...

Date of Patent

December 6, 2016

Patent Application Number

128806230

Date Filed

September 13, 2010

Patent Primary Examiner

‌

Zachary Skelding

Patent abstract

The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg.